ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Effects of Esketamine Infusion by Patient-Controlled Intravenous Analgesia in Patients With Zoster-Associated Pain: A Retrospective Study.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Esketamine has been used for the management of acute and chronic pain. This study aimed to evaluate the effects of patient-controlled intravenous analgesia (PCIA) with esketamine on zoster-associated pain during the subacute stage. MATERIAL AND METHODS This retrospective study analyzed 86 patients treated at Ningbo Medical Center Lihuili Hospital between January 1, 2024, and September 1, 2024. Patients were divided into an esketamine group (group ES, n=44) and a control group (group C, n=42). Group ES received intravenous esketamine via PCIA for 5 days, whereas group C received 0.9% saline. Both groups underwent pulsed radiofrequency treatment. Numeric rating scale (NRS) scores, Pittsburgh Sleep Quality Index (PSQI) scores, postoperative analgesic consumption, incidence of postherpetic neuralgia, Central Sensitization Index (CSI) scores, and adverse events were assessed before and after treatment. RESULTS Group ES demonstrated significantly lower NRS and PSQI scores at 1 week (NRS: Z=2.075, P=0.038; PSQI: Z=4.224, P<0.001) and 4 weeks (NRS: Z=2.117, P=0.034; PSQI: Z=5.775, P<0.001). Tramadol and pregabalin consumption did not differ between groups at 1, 4, 12, or 24 weeks (P>0.01). The postherpetic neuralgia rate was 25.00% in group ES and 42.86% in group C (χ²=3.066, P=0.08). CSI scores differed at 12 weeks (t=2.591, P=0.011) and 24 weeks (t=2.135, P=0.036). Group ES had higher incidences of dizziness, nausea, and vomiting, but lower incidences of rebound pain and constipation. CONCLUSIONS Esketamine was associated with reduced pain intensity and improved sleep quality in patients with zoster-associated pain during the early posttreatment period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.